NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Get Free Report) shares crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $2.76 and traded as high as $2.91. NRx Pharmaceuticals shares last traded at $2.80, with a volume of 2,108,875 shares trading hands.
Wall Street Analyst Weigh In
Several research firms have weighed in on NRXP. Wolfe Research started coverage on NRx Pharmaceuticals in a research note on Thursday, October 15th. They set an “outperform” rating for the company. Wall Street Zen lowered NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Tuesday, November 3rd. Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday. Finally, UBS Group reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.
Read Our Latest Stock Analysis on NRXP
NRx Pharmaceuticals Stock Down 15.7%
The stock has a 50 day moving average price of $2.72 and a 200 day moving average price of $2.97. The stock has a market capitalization of $93.85 million, a price-to-earnings ratio of -6.32 and a beta of 2.11.
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.16. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.28 million. Sell-side analysts forecast that NRx Pharmaceuticals, Inc. will post -1.14 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in NRXP. B Group Inc. boosted its position in NRx Pharmaceuticals by 4.5% during the third quarter. B Group Inc. now owns 4,277,200 shares of the company’s stock valued at $12,489,000 after acquiring an additional 185,433 shares during the last quarter. Marshall Wace LLP grew its stake in NRx Pharmaceuticals by 411.4% during the third quarter. Marshall Wace LLP now owns 995,172 shares of the company’s stock worth $2,906,000 after purchasing an additional 800,592 shares during the period. Commonwealth Equity Services LLC increased its holdings in NRx Pharmaceuticals by 30.0% in the third quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock worth $1,725,000 after purchasing an additional 136,350 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in NRx Pharmaceuticals by 292.1% in the third quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company’s stock worth $58,000 after purchasing an additional 14,900 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC acquired a new position in NRx Pharmaceuticals in the third quarter valued at approximately $364,000. Institutional investors own 4.27% of the company’s stock.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.
Further Reading
- Five stocks we like better than NRx Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
